Japan Diabetes Device Market Forecast Report by Types (Self-Monitoring Devices, Continuous Glucose-Monitoring Devices, Insulin Pumps, Insulin Pens), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies) and Company Analysis 2024-2032
Buy NowJapan Diabetes Device Market Size
Japan Diabetes Device market is expected to reach US$ 1.46 Billion in 2023 to US$ 2.80 Billion by 2032, with a CAGR of 7.49 % from 2024 to 2032. The market is growing primarily due to significant developments and technology advancements that address the complex demands of managing, monitoring, and treating diabetes.
Japan Diabetes Device Overview
Japan boasts one of the world's largest senior populations, making it more prone to the emergence of type 2 diabetes. Diabetes is becoming more common in Japan as the country's population ages. Blood glucose monitoring and treatment are becoming more common in order to prevent adverse outcomes like kidney problems, cardiovascular illnesses, and many other ailments.
The need for diabetes devices is being driven by Japan's increasing diabetes prevalence, which has emerged as a serious health concern. Italy's diabetes diagnosis rate has been steadily rising due to changes in lifestyle, such as sedentary behavior, bad eating habits, and an aging population. Japan is one of the Asian nations with the highest prevalence of diabetes, accounting for the disease's burden from both type 1 and type 2 diabetes, according to recent figures. IDF 2021 statistics estimates that 11 million persons in Japan have diabetes.
The need for efficient management and treatment alternatives is rising in tandem with Japan's diabetes population growth. Diabetes devices are essential for managing blood sugar levels and avoiding problems related to the disease. Many patients choose these drugs because they are easy to take, convenient, and can help with glycemic control. The need for affordable and effective therapies to counteract Japan's rapidly spreading diabetes epidemic is reflected in the demand for diabetes gadgets.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 1.46 Billion |
|
Market Forecast in 2032 |
US$ 2.80 Billion |
|
Market Growth Rate (2024-2032) |
7.49% |
Growth Drivers for the Japan Diabetes Device Market
Government campaigns are a major factor in encouraging the use of diabetes management device in Japan
In order to improve the treatment of diabetes, the Ministry of Health, Labour and Welfare (MHLW) has introduced public health campaigns and nationwide screening programs, among other supportive healthcare measures. The ultimate goal of these programs is to lower the long-term consequences linked to diabetes by concentrating on early detection and intervention. The government is promoting awareness and encouraging patients to use accessible technologies by giving diabetes treatment a high priority in public health agendas.
Furthermore, the Japanese healthcare system reimburses the cost of a number of diabetes management devices, such as insulin pumps and continuous glucose monitors. Patients' burdens are lessened by this financial assistance, increasing the accessibility of these gadgets. Reimbursement policies encourage medical professionals to suggest advanced diabetes management strategies, leading to a change in treatment regimens that are more efficacious. Consequently, these government initiatives greatly raise the nationwide adoption rate of cutting-edge diabetes gadgets.
Increased public knowledge of diabetes prevention and management
Governmental and healthcare institutions have launched awareness programs emphasizing the value of knowing about diabetes, its dangers, and practical management techniques. These programs attempt to demystify and lessen the stigma associated with diabetes by emphasizing healthy lifestyles, early identification, and the vital role that technology plays in diabetes treatment. People who are more aware of the dangers of diabetes are more inclined to take preventative steps, such as using cutting-edge medical technology.
Furthermore, social media and community health initiatives have been essential in spreading knowledge and promoting conversations about managing diabetes. People are more inclined to take control of their health as a result of this increased awareness, which increases acceptability of devices like insulin pumps and continuous glucose monitors. As a result, the general market demand for these devices is rising as more people become aware of their advantages.
Japan Diabetes Device Company Analysis
The major participants in the Japan Diabetes Device market includes Abbott Laboratories, Roche, Medtronic, Novo Nordisk A/S, Terumo Corporation, Eli Lilly, BD, Dexcom Inc.
Japan Diabetes Device Company News
In December 2022, A press statement from Terumo Company states that the Japanese medical insurance system now offers greater payment coverage for the Dexcom G6 CGM System. A larger number of diabetic patients in Japan will be qualified to request reimbursement for utilizing the Dexcom G6 CGM System as a result of the recently established "C150" category.
In March 2022, The Japanese Ministry of Health, Labour, and Welfare has authorized extending the Freestyle Libre system's payment coverage to encompass all diabetics who take insulin at least once daily, according to a statement from Abbott.
Types- Industry is divided into 4 viewpoints:
- Self-Monitoring Devices
- Continuous Glucose-Monitoring Devices
- Insulin Pumps
- Insulin Pens
Distribution Channel - Industry is divided into 4 viewpoints:
- Hospital Pharmacies
- Retail Pharmacies
- Diabetes Clinics/Centers
- Online Pharmacies
All companies have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
Company Analysis
- Abbott Laboratories
- Roche
- Medtronic
- Novo Nordisk A/S
- Terumo Corporation
- Eli Lilly
- BD
- Dexcom Inc
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Billion |
| Segment Covered | Types and Distribution Channel |
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Japan Diabetes Devices Market
6. Japan Diabetes Population
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes
7. Market Share Analysis
7.1 By Types
7.2 By Distribution Channel
8. Types
8.1 Self-Monitoring Devices
8.1.1 Test Strips
8.1.2 Lancets
8.1.3 Blood Glucose Meters
8.2 Continuous Glucose-Monitoring Devices
8.2.1 Sensors
8.2.2 Transmitter
8.2.3 Receiver
8.3 Insulin Pumps
8.3.1 Patch Pumps
8.3.2 Tethered Pumps
8.3.3 Consumables
8.4 Insulin Pens
8.4.1 Disposable Insulin Pen
8.4.2 Reusable Insulin Pen
9. Distribution Channel
9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Diabetes Clinics/Centers
9.4 Online Pharmacies
10. Porters Five Forces
10.1 Bargaining Power of Buyer
10.2 Bargaining Power of Supplier
10.3 Threat of New Entrants
10.4 Rivalry among Existing Competitors
10.5 Threat of Substitute Products
11. SWOT Analysis
11.1 Strengths
11.2 Weaknesses
11.3 Opportunities
11.4 Threats
12. Reimbursement Policies
12.1 CGM Devices in Japan
12.2 Blood Glucose Devices in Japan
12.3 Insulin Pump Products in Japan
12.4 Insulin Pen in Japan
13. Key Players Analysis
13.1 Abbott Laboratories
13.1.1 Overviews
13.1.2 Key Person
13.1.3 Recent Developments & Strategies
13.1.4 Product Portfolio & Product Launch in Last 1 Year
13.1.5 Revenue
13.2 Roche
13.2.1 Overviews
13.2.2 Key Person
13.2.3 Recent Developments & Strategies
13.2.4 Product Portfolio & Product Launch in Last 1 Year
13.2.5 Revenue
13.3 Medtronic
13.3.1 Overviews
13.3.2 Key Person
13.3.3 Recent Developments & Strategies
13.3.4 Product Portfolio & Product Launch in Last 1 Year
13.3.5 Revenue
13.4 Novo Nordisk A/S
13.4.1 Overviews
13.4.2 Key Person
13.4.3 Recent Developments & Strategies
13.4.4 Product Portfolio & Product Launch in Last 1 Year
13.4.5 Revenue
13.5 Terumo Corporation
13.5.1 Overviews
13.5.2 Key Person
13.5.3 Recent Developments & Strategies
13.5.4 Product Portfolio & Product Launch in Last 1 Year
13.5.5 Revenue
13.6 Eli Lilly
13.6.1 Overviews
13.6.2 Key Person
13.6.3 Recent Developments & Strategies
13.6.4 Product Portfolio & Product Launch in Last 1 Year
13.6.5 Revenue
13.7 BD
13.7.1 Overviews
13.7.2 Key Person
13.7.3 Recent Developments & Strategies
13.7.4 Product Portfolio & Product Launch in Last 1 Year
13.7.5 Revenue
13.8 Dexcom Inc
13.8.1 Overviews
13.8.2 Key Person
13.8.3 Recent Developments & Strategies
13.8.4 Product Portfolio & Product Launch in Last 1 Year
13.8.5 Revenue
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com